AI can augment oncology nursing through symptom triage support, trial matching, care plan personalization, pharmacogenomics ...

Learn the risk factors, symptoms and screening options tied to colorectal cancer as cases continue rising among younger ...

Ongoing annual imaging of the remaining breast, plus peer navigation and patient self-advocacy, are framed as practical ...

Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, ...

Melanoma patients preparing for inpatient TIL therapy learn what to pack, how chemo feels, and how IL‑2 side effects are managed. Close monitoring during interleukin-2 (IL-2) therapy is essential for ...

Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...

Researchers at Moffitt Cancer Center are studying a new topical therapy called DYV800 that may help the immune system fight ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

New research shows that lymphoma survivors often face long-term peripheral neuropathy, which may be more severe than what ...

FDA approved adjuvant atezolizumab for post-cystectomy MIBC with ctDNA MRD positivity, alongside Signatera CDx as the required companion diagnostic for eligibility determination. IMvigor011 randomized ...

Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.